Schrödinger, Inc. just delivered its Q2 results on August 5, and the stock's 2.4% bounce on the day marks the first meaningful reprieve in a difficult month — the question now is whether bears, who held a substantial position heading into the print, are beginning to reassess.
The short position heading into results was genuinely elevated. Bears held 16.4% of the free float at last count, essentially flat on the week — short interest barely moved, edging down 0.5% on the day and up just 0.05% over the trailing week. That stability matters: it tells you the 2.4% price gain was not accompanied by any rush to cover. The ORTEX short score has eased fractionally from its July peak of 70.9 to 70.6, but remains firmly in elevated territory, reflecting a structural rather than tactical short book. Days-to-cover from FINRA data is 9.75 — nearly two full trading weeks at normal volume. The borrow market, as it has been all month, offers no mechanical pressure: availability runs at 253%, meaning roughly two-and-a-half shares remain lendable for every one already borrowed, and cost to borrow is just 0.47%. Bears are sitting comfortably — for now.
Options positioning is equally calm after the number. The put/call ratio of 0.58 is barely a quarter of a standard deviation above its 20-day average of 0.58. That is effectively neutral. The 52-week range runs from 0.10 to 0.69, so the current reading lands near the middle — neither crowded with protection buyers nor reflecting fresh bullish call demand. Peer gained 5.3% on the week and added 8%, suggesting the broader health care technology cohort has had a strong run. Against that backdrop, SDGR's 2.4% weekly gain looks like underperformance, not a breakout.
The Street remains constructive on paper but has been steadily trimming targets for months. The consensus sits at Buy, with a mean target around $20.57 — roughly 31% above the current price of $15.65. However, the direction of recent analyst activity tells a more cautious story: Morgan Stanley cut its target to $17 in May (still current), Keybanc lowered to $20 in April, and UBS trimmed to $13 in March. No firm has raised targets in recent months. The factor scores reinforce the mixed read — earnings surprise ranks in the 83rd percentile, which is genuine strength, but forward EPS momentum is deeply weak at just the 3rd percentile, and the short score rank sits at the 5th percentile of the universe, meaning very few stocks carry a more bearish ORTEX short profile.
Ownership context adds one more layer. The Gates Foundation Trust holds 21.6% of shares — effectively an anchor position that has not moved. Rubric Capital added 1.8 million shares in Q1, bringing its stake to 8%. ARK added modestly in July, reporting 73,000 shares of new buying through July 31. Insider flow has been entirely one-directional: CEO Ramy Farid sold $525,000 worth of shares in April, the CFO sold a smaller lot in July, and no insider has bought in the trailing 90 days. Net insider activity is a net sale of roughly $539,000 over that period — light in absolute terms, but conspicuously lacking any buy-side conviction from management heading into results.
The prior two earnings releases show a split pattern: a 4.6% drop the day after the June print, then a 10.3% recovery over the following five sessions; the May print saw a modest 3.2% gain on the day. With the Q2 number now out and the stock mildly higher, the setup to watch is whether the short book — which sat through a difficult July without budging — begins to thin as the next catalyst recedes or whether the weak forward earnings momentum keeps bears anchored through the autumn reporting season.
See the live data behind this article on ORTEX.
Open SDGR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
